Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ivana N. M. Micallef"'
Autor:
Karan Chohan, Jason R. Young, Scott Lester, Muhamad Alhaj Moustafa, Allison Claire Rosenthal, Han W. Tun, Bradford Hoppe, Patrick B. Johnston, Ivana N. M. Micallef, Thomas Matthew Habermann, Stephen M. Ansell
Publikováno v:
Journal of Clinical Oncology. 40:e19532-e19532
e19532 Background: The traditional approach to the treatment of early-stage classical Hodgkin lymphoma (cHL) has been combined modality therapy (CMT) with both chemotherapy and radiotherapy (RT). CMT has shown improved disease control, but RT can lea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2fc9e9587676211c7c6eb2db483719b
https://doi.org/10.1200/jco.2022.40.16_suppl.e19532
https://doi.org/10.1200/jco.2022.40.16_suppl.e19532
Autor:
Sanjal Desai, Michael Alexander Spinner, Kevin A. David, Veronika Bachanova, Gaurav Goyal, Raya Saba, Kathleen Anne Dorritie, Jacques Mario Azzi, Elyse Harris, Brendon Fusco, Nuttavut Sumransub, Haris Hatic, Uroosa Ibrahim, Siddharth Iyengar, Katherine Cynthia Rappazzo, Firas Baidoun, Victor Manuel Orellana-Noia, Catherine S. Magid Diefenbach, Ranjana H. Advani, Ivana N. M. Micallef
Publikováno v:
Journal of Clinical Oncology. 40:7515-7515
7515 Background: Primary refractory disease (PRD) and early relapse (ER) are predictors of poor prognosis in classic Hodgkin lymphoma (cHL). In this multicenter retrospective study, we describe outcomes of PRD and ER in pts with relapsed/refractory (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec10715e3dcaa5b6c8d32cb4defad686
https://doi.org/10.1200/jco.2022.40.16_suppl.7515
https://doi.org/10.1200/jco.2022.40.16_suppl.7515
Autor:
Thomas E, Witzig, Matthew J, Maurer, Thomas M, Habermann, Brian K, Link, Ivana N M, Micallef, Grzegorz S, Nowakowski, Stephen M, Ansell, Joseph P, Colgan, David J, Inwards, Luis F, Porrata, Svetomir N, Markovic, Patrick B, Johnston, Yi, Lin, Carrie, Thompson, Mamta, Gupta, Jerry A, Katzmann, James R, Cerhan
Publikováno v:
American journal of hematology. 89(12)
The serum immunoglobulin free light chain (FLC) assay quantitates free kappa (κ) and lambda (λ) light chains. FLC elevations in patients with diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and chronic lymphocytic leukemia (CLL) are a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8269e11d658347de9f10a2144c134ee2
https://pubmed.ncbi.nlm.nih.gov/25228125
https://pubmed.ncbi.nlm.nih.gov/25228125